Anti CD38 monoclonal antibodies for multiple myeloma treatment
Monoclonal antibody-based therapy has revolutionized MM therapy in the latest years increasing depth of response. This product review will focus on anti-CD38 monoclonal antibodies …
A Novel Anti-CD38 Monoclonal Antibody for Treating Immune ...
2024年6月19日 · In this study, anti-CD38 targeted therapy rapidly boosted platelet levels by inhibiting antibody-dependent cell-mediated cytotoxicity on platelets, maintained long-term …
CD38 antibodies in multiple myeloma: back to the future
2018年1月4日 · CD38 is a transmembrane glycoprotein with ectoenzymatic activity, and also functions as a receptor and adhesion molecule. Altogether, this has triggered the development …
Real world data on outcomes of anti-CD38 antibody treated
2023年12月8日 · Patients with triple class refractory (TCR) disease (refractory to a proteasome inhibitor, immunomodulatory drug, and anti-CD38 mAb) were examined as a distinct cohort.
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action …
CD38 antibodies kill tumor cells via Fc-dependent immune effector mechanisms including complement-dependent cytoxicity (CDC), antibody-dependent cell-mediated cytotoxicity …
CD38-Directed Therapies for Management of Multiple Myeloma
Antibody-based therapies targeting the surface marker CD38, namely daratumumab and isatuximab, have emerged as being highly effective as single agents as well as in combination …
CD38 antibodies in multiple myeloma: back to the future
2018年1月4日 · CD38-targeting antibodies are generally well tolerated and induce partial response or better in ∼30% of heavily pretreated MM patients as monotherapy. Based on their …
Frontiers | CD38 Antibodies in Multiple Myeloma: Mechanisms of …
2018年9月19日 · CD38 antibodies kill tumor cells via Fc-dependent immune effector mechanisms including complement-dependent cytoxicity (CDC), antibody-dependent cell-mediated …
Anti-CD38 antibody therapy for patients with relapsed/refractory ...
2022年8月9日 · Two monoclonal antibodies directed at CD38, isatuximab and daratumumab, are available for use in patients with relapsed and/or refractory MM (RRMM); daratumumab is also …
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and ... - PubMed
2018年9月20日 · Inhibition of ectoenzymatic function and direct apoptosis induction may also contribute to the efficacy of the antibodies to kill MM cells. The CD38 antibodies also improve …
- 某些结果已被删除